Antiallergic activity profiles in vitro of RHC 3164 and related compounds. II. Comparison of RHC 3164 with disodium cromoglycate.
RHC 3164 has been investigated for its antiallergic activities in 3 in vitro models of anaphylaxis. RHC 3164 was 6 times more potent than DSCG as an inhibitor of antigen-induced release of histamine (AIR) from rat mast cells (RMC) and had an activity profile identical to that of DSCG in the following respects: loss of inhibitory activity with increasing preincubation time, tachyphylactic properties, cross-tachyphylaxis to DSCG, and inability to inhibit nonimmunologic release of histamine. Neither RHC 3164 nor DSCG had any effect on immunologic release of histamine from human basophils or guinea pig lung slices. We conclude that RHC 3164 is a potent inhibitor of immunologic release of histamine from RMC with a mechanism of action similar to that of DSCG.
D000818:Animals; D001491:Basophils / Q000276:immunology; D000001:Calcimycin / Q000494:pharmacology; D004205:Cromolyn Sodium / Q000494:pharmacology*; D003911:Dextrans / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D008168:Lung / Q000276:immunology; D008407:Mast Cells / Q000276:immunology; D010718:Phosphatidylserines / Q000494:pharmacology; D051381:Rats; D013618:Tachyphylaxis; D013997:Time Factors; D014230:Triazoles / Q000494:pharmacology*
D003911:Dextrans; D006634:Histamine H1 Antagonists; D010718:Phosphatidylserines; D014230:Triazoles; D000001:Calcimycin; C040270:7-chloro-5-propyl-1,2,4-triazolo(4,3-a)quinoxaline-1,4(2H,5H)-dione; D004205:Cromolyn Sodium